Stay updated on Menin Inhibitor Combo in AML Clinical Trial

Sign up to get notified when there's something new on the Menin Inhibitor Combo in AML Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Menin Inhibitor Combo in AML Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    No Change Detected
  4. Check
    3 days ago
    No Change Detected
  5. Check
    4 days ago
    No Change Detected
  6. Check
    5 days ago
    Change Detected
    Summary
    The value -22 04 18 -22 04 7 has been updated to 06- 06 02 06- 06 8 on the webpage. This change likely reflects an update in the dosing or treatment regimen for the clinical research study investigating the combination of SNDX-5613, ASTX727, and venetoclax for patients with acute myeloid leukemia.
    Difference
    0.7%
    Check dated 2024-06-06T14:47:04.000Z thumbnail image
  7. Check
    20 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to 'Researchers look for people who fit a certain description, called eligibility criteria,' with additional details on examples of these criteria and a link for more information about clinical research. The specific eligibility criteria for the study have also been expanded to include detailed inclusion and exclusion criteria.
    Difference
    37%
    Check dated 2024-05-22T21:33:18.000Z thumbnail image
  8. Check
    42 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:33:28.000Z thumbnail image

Stay in the know with updates to Menin Inhibitor Combo in AML Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Menin Inhibitor Combo in AML Clinical Trial page.